Background/Aims: The expression of estrogen receptor-α (ERα) is one of the most important diagnostic and prognostic factors of breast cancer. Recently, ERα-36 has been identified as a novel variant of ER-α. ERα-36 lacks intrinsic transcription activity and mainly mediates nongenomic estrogen signaling. The noncanonical IKK family member IKKε is essential for regulating antiviral signaling pathways and is recently discovered as a breast cancer oncogene. IKKε interacts with and phosphorylates ERα on serine 167, induces ERα transactivation activity and enhances ERα binding to DNA in ER-positive breast cancer cells. However, the correlation between IKKε and the ERα-36 signaling pathway in ER-negative breast cancer cells remains unclear. Methods and Results: In this study, we show that IKKε interacts with ERα-36 and increases its expression in breast cancer cells. As shown by western blot assays, the upregulation of ERα-36 by IKKε was significant. In MDA-MB-231 cells which are ER-negative, IKKε was able to increase the expression of ERα-36 in a dose-dependent manner, and the RNA interference assay indicated the correlation between IKKε and ERα-36 expression. Moreover, IKKε enhanced the growth of MDA-MB-231 and MDA-MB-436 cells. Conclusions: These results suggest that IKKε increases ERα-36 expression and is involved in ERα-36 mediated non-genomic estrogen signaling.
Introduction
Breast cancer is the most common cancer among women, the ER signaling pathway plays a pivotal role in the development of different types of breast cancer [1, 2] . Two types of ERs have been identified, ERα and ERβ [3, 4] . There are 3 types of ERα isoforms identified: 66-KD, 46-KD and 36-KD [5] . Tumors expressed ERα-66 were considered as ERα-positive [6] . Previous studies indicated that approximately 70% of these tumors express estrogen receptor α [7] . Patients with ERα-positive tumors are associated with a well differentiated phenotype and have a better prognosis; ER-negative tumors had a shorter disease-free interval and overall survival than patients with ER-positive tumors [8] . Although significant progress has been made in the development of endocrine therapies that target estrogen or ER for ER-positive tumors, there is no effective therapy for the 30% of breast cancers that are ER negative [9, 10] . Recently, a 36-kDa variant of ERα-66, named ER-a36 has been identified, it is mainly expressed in the cytoplasm and plasma membrane and has minimal or no nuclear expression in breast cancer cells [11] [12] [13] . ERα-36 was expressed in ER-negative tumor samples and ER-negative breast cancer cell lines [14] . Some studies have suggested that ERα-36 is involved in nongenomic estrogen signaling, and ERα-36 promotes cell proliferation via the MAPK/ERK pathway in ER-negative breast cancers [13, 14] .
IKKε is one of noncanonical IKK family member that plays a critical role in the regulation of interferon signaling pathways [15] [16] [17] . When IKKε was activated, interferon regulatory factors 3 and 7 (IRF3 and IRF7) were phosphorylated, allowing their nuclear translocation and the transcriptional upregulation of genes involved in the type I interferon response. IKKε also phosphorylates STAT1 following activation by IFNb [18] . IKKε had been identified IKKε as a breast cancer oncogene amplified and overexpressed in over 30% of breast carcinomas and breast cancer cell lines [19] . Recently, it has also been demonstrated that IKKε phosphorylates Ser-167 of ERα, and induction of ERα transactivation contributes to tamoxifen resistance in breast cancer [20] .
In this study, we show for the first time that IKKε increases the expression of ERα-36 in MDA-MB-231 and MDA-MB-436 breast cancer cell lines. We further show that IKKε interacts with ERα-36. The results from our study also show that IKKε is involved in ERα-negative breast cancer cell growth through regulation of ERα-36 mediated mitogenic estrogen signaling, identifying a novel mechanism by which IKKε are constitutively activated in ERα-negative breast cancer cells.
Materials and Methods

Chemicals and antibodies
The 17β-estradiol (E 2 β) was obtained from Sigma. The IKKε(I-4907), HA(H-6908), Flag(F-1804), β-actin(A-1978) antibodies were obtained from Sigma. The ERα-36 antibody (CY1109) was obtained from Cell Applications. Cyclin D1(H-295), c-Myc(9E10) were obtained from Santa Cruz Biotechnology. IKKε (sc-39056) siRNA was obtained from Santa Cruz Biotechnology.
Cell lines, treatment and growth assay MDA-MB-231, MDA-MB-436 cells and human embryonic kidney cell line (HEK293) were obtained from the American Type Culture Collection (ATCC). All cells were maintained in Dulbecco's modied Eagle's medium and 10% fetal calf serum at 37°C in a 5% CO 2 incubator. For E 2 β treatment, cells were maintained in phenolred-free media with 2.5% charcoal-stripped fetal calf serum (HyClone, Logan, UT, USA) for 3 days and then in serum-free medium for 24 h before experimentation.
To cell growth assays, cells were treated with indicated concentrations of E 2 β or vehicle (ethanol) as a control. The cells were seeded at 1×10 4 cells per dish in 60mm dishes and the cell numbers were determined using the ADAM automatic cell counter (Invitrogen, USA) after 12 days. Five dishes were used for each treatment and experiments were repeated more than three times. 
DNA Transfection and Luciferase Assays
For transient transfection assays, cells were seeded in six-well dishes and grown to 60-70% confluence in phenol-red-free medium plus 2.5% steroid-free FCS. Cells were washed and transiently transfected with a total of 5ug of plasmid with the FuGene6 reagent (Roche Molecular Biochemicals). The luciferase assays were performed by using the Luciferase Assay kit from Promega according to the manufacturer's recommendations. The Gal4 L-ELK plasmid was purchased from Stratagene. At 48 h after transfection, cell extracts were prepared and luciferase activities were determined and normalized using the Dual-Luciferase Assay System (Promega).
Immunoprecipitation and immunoblot analysis
For immunoprecipitation assays, cells were washed twice with ice-cold phosphate buffered saline and lysed with the lysis buffer (150mM NaCl, 20mM Tris-HCl, pH 7.4, 0.1% NP-40) supplemented with protease and phosphatase inhibitors (Roche). Cell lysates were then incubated with indicated primary antibodies or pre-immune serum and immunoprecipitated with protein A/G plus agarose. The precipitates were then washed, separated on SDS-polyacrylamide gel electrophoresis and analyzed with western blot analysis.
For Western blot analyses, cells were disrupted with RIPA buffer, and the cell lysates were boiled in a gel-loading buffer and separated by SDS-PAGE in 10% gels. After PAGE, the proteins were transferred to a poly vinylidene difluoride membrane (Millipore), and visualized with the appropriate species-specific peroxidase-conjugated secondary Abs (Santa Cruz Biotechnology) and enhanced chemiluminescence (ECL) reagents (Amersham Pharmacia).
Immunohistochemistry
Tumor tissues were collected from 25 cases of patients with ER-negative breast carcinomas with informed consent in Jinan Military General Hospital (Jinan, China). The design of the study was approved by the Hospital Ethical Committee. Immunohistochemistry (IHC) was carried out based on the method described before. Briefly, antigen retrieval was performed using 10 mM sodium citrate buffer (pH 6.0) in a 95°C water bath for 15 minutes. Then primary antibody was used overnight at 4 °C in a humidified chamber, followed by secondary antibody.
Statistical analysis
Statistical analysis was carried out using the Statistical Package for Social Sciences 13.0 (SPSS). Data are presented as the means ± SEM. Statistical significance was determined by a one-way analysis of variance or the t-test. P-values <0.05 were considered to indicate statistically significant differences.
Results
IKKε interacts with ERα-36
Because IKKε interacts with the ERα-66, which has conserved domains similar to those of ER-α, we next examined whether ERα-36 interacts with IKKε. The coimmunoprecipitation was performed in HEK-293T cells, which had been transfected with HA-ERα-36 and Flag-IKKε. ERα-36 was detected in flag-IKKε immunoprecipitates (Fig. 1A) . Furthermore, endogenous ERα-36 and IKKε were able to form a complex in MDA-MB-231 cells (Fig. 1, B and C) , which express ERα-36 as well as high levels of IKKε .These findings indicate that ERα-36 interacts with IKKε. To further explore the molecular basis of the interaction between IKKε and ERα-36, the regions of IKKε were defined. Results of co-immunoprecipitation experiment showed that the kinase domain (1-290 amino acids) of IKKε were indispensable for their interaction (Fig. 1D) . In order to obtain evidence of direct IKKε phosphorylation of ERα-36, recombinant GST-ERα-36 was incuba- (Fig. 1E) .
IKKε increase the expression of the ERα-36 protein
To explore the possible effects of IKKε on ERα-36, we first examined whether IKKε affects ERα-36 expression. HEK-293T cells were cotransfected with Flag-tagged IKKε and HA-ERα-36. The protein levels of ERα were greatly increased by WT IKKε. In contrast, kinase dead mutant of IKKε (K38A) resulted in a complete abolished IKKε-mediated ERα-36 upregulation ( Fig. 2A) . Furthermore, overexpression of IKKε in ERα-negtive breast cancer cell lines (MDA-MB-231 and MDA-MB-436) leads to increase the endogenous protein levels of ERα-36. Similarly, overexpression of IKKε (K38A) mutation abolished IKKε-mediated endogenous ERα-36 upregulation in these cell lines (Fig. 2B) . In addition, decreasing the endogenous amount of IKKε in human MDA-MB-231 and MDA-MB-436 cells with IKKε siRNA oligos led to decrease the endogenous protein levels of ERα-36, and this phenotype was reversed by cotransfected with IKKε (res) plasmid and IKKε siRNA oligos (Fig. 2C) . Therefore, we suggest that IKKε-mediated increase of ERα-36 protein expression, and this effect probably mediated by IKKε kinase activitys. Moreover, deletion of the kinase domain of IKKε abolishes the IKKε-induced increase the expression of ERα-36 (Fig. 2D) . In order to explore whether IKKε regulates ERα-36 at transcriptional level, Realtime-PCR analysis was done. Realtime-PCR analysis showed no significant difference in the transcriptional level of ERα-36 by IKKε overexpression (Fig. 2E) .
IKKε enhance ERα-36 mediated mitogenic estrogen signaling in ER-negative breast cancer cells
Previous reports have indicated that ERα-36 mediates mitogenic estrogen signaling in ERnegative breast cancer cells. E 2 β stimulates a rapid activation of the MAPK/ERK pathway mediated by ERα-36. Consequently, E 2 β was also able to induce expression of the growth-promoting genes c-Myc and cyclin D1. We then decided to determine whether IKKε impact the estrogen-Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry activated MAPK pathway mediated by ERα-36, we use a luciferase reporter construct containing the ERK-responsive transactivation domain of human Elk, which is a downstream effector of the MAPK/ERK signaling pathway. The HEK-293T cells were transfected with ERK-responsive GALElk chimeric transcription factor and GAL4 fused ERK-responsive transactivation domain of Elk1.
The activity of a luciferase reporter gene containing GAL4-binding sites in the presence of E 2 β was measured. E 2 β treatment of IKKε and ERα-36 cotransfected cells induced increase of Elk/ Gal4 fusion protein-mediated transactivation of the reporter gene than transfected with ERα-36 alone, whereas no effect on the transcription activity of the Elk/Gal4 fusion protein in the control cells transfected with empty vector or E 2 β absence cells (Fig. 3A) . Furthermore, IKKε transfected cells also increase transcription activity of the Elk/Gal4 than transfected with empty vector in ER-negative breast cancer cells (MDA-MB-231 and MDA-MB-436), whereas no effect on the transcription activity of the Elk/Gal4 in the cells transfected with siRNA oligos or E 2 β absence cells (Fig. 3B and C) . Consequently, IKKε was also able to enhance expression of the growth-pro- Li
for p-ERK was significantly enhanced by overexpressed IKKε, whereas this increased phosphorylation was greatly reduced by ERα-36 siRNA oligos (Fig. 3F) . These results demonstrated that IKKε enhance ER-α36 mediated mitogenic estrogen signaling.
IKKε promote ER-negative breast cancer cell growth mediated by ERα-36
To further pursue the significance of IKKε-ERα-36 interaction, we tested whether IKKε impact ERα-36 mediates estrogen-stimulated cell proliferation. In assays of anchorage-dependent growth, MDA-MB-231 cells and MDA-MB-436 cells transfected with IKKε grew faster than those transfected with empty vector with E 2 β treated, whereas IKKε had no effect on the growth of the control MDA-MB-231 cells without E 2 β treated ( Fig. 4A and B) . ERα-36 knockdown almost completely abolished IKKε-mediated growth stimulation of MDA-MB-231 cells (Fig. 4C) . In order to further support the role of IKKε in ERα-negative breast cancer as well as to substantiate the functional link between IKKε and ERα-36 and extend the physiological relevance of this link, we collected 25 ERα-negative breast cancer samples from breast cancer patients. The expression of IKKε and ERα-36 was analyzed by immunohistochemistry staining with an antibody of IKKε and ERα-36. The results suggested that IKKε had a significant positive correlation with ERα-36 expression (P = 0.036, r = 0.384) (Fig. 4 D) .
Discussion
Breast cancer is the most common malignant tumor which is the leading cause of cancer-related deaths in women worldwide [21] . ER-α expression is one of the most important responses to endocrine therapy [22] . Approximately 70% of breast cancer cases are ERα-positive, and the remaining 30% are ER-negative [10] . ERα-36 is a variant of conventional ERα, which lacks both transcriptional activation domains of ERα-66, retains DNA-binding domain, partial dimerization and ligand-binding domains, and possesses a unique 27 amino acid domain that replaces the last 138 amino acid of ERα-66 [11, 13] . It was found that ERα-36 expression levels were higher in ERnegative tumors and lower in ER-positive tumors [12] . ER-α36 mediated mitogenic estrogen signaling in ER-negative breast cancer cells, such as MDA-MB-231 and MDA-MB-436 cells that lack Cellular Physiology and Biochemistry expression of ER-α66 but highly express ER-α36. It was reported that E 2 β induced the MAPK/ ERK activation through a mechanism that involves ER-α36 and the EGFR/Src/Shc complex and exhibited a potent mitogenic estrogen signaling in vitro and in vivo [11, 12, 14] .
In the present study, we identified that IKKε interacts with ERα-36, increases the expression of ERα-36 in MDA-MB-231 and MDA-MB-436 breast cancer cells. Additionally, IKKε enhances ERα-36 mediated mitogenic estrogen signaling and promotes ER-negative breast cancer cell growth mediated by ERα-36.
IKKε is a member of IKK family, and shares 30% amino acid identity with IKKα and IKKβ in their kinase domains [15] . IKKε plays a central role in regulating innate immunity by activating the NF-κB signaling pathway and phosphorylating IRF3 and IRF7 to regulate the type I interferon response [16] . IKKε also phosphorylates the tumor suppressor CYLD and promotes cell transformation [23] . In addition, recent study indicated that IKKε is amplified in a substantial percentage of human breast tumors and acts as an oncogene in breast cancers [19] . Especially, IKKε phosphorylates ERα on Ser-167 site, leading to activation of ERα and up-regulation of cyclin D1. Furthermore, overexpression of IKKε in ERα-positive breast cancer cells induces tamoxifen resistance [20] . This effect mainly required kinase activity of IKKε. In this study, we found that kinase lethal mutant of IKKε (K38A) resulted in a complete abolished IKKε-mediated ERα-36 upregulation, indicating that ERα-36 may be a new IKKε kinase substrate.
In summary, we have shown that breast oncogene IKKε interacts with ERα-36, and increases ERα-36 expression in ER-negative breast cancer cells. In addition, IKKε increases ERα-36 mediated MAPK/ERK signaling pathway, and enhances nongenomic estrogen signaling, contributing to development and progression of ER-negative breast cancer cells. Therefore, IKKε plays important roles in breast cancer tumorigenesis, and may be a very effective target for breast cancer therapy through regulating multiple signaling pathways.
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